From DCAT Value Chain Insights (VCI)
GlaxoSmithKline (GSK) reports that Dr. Moncef Slaoui, chairman, vaccines, has indicated to the company's board of his intention to retire from the company in 2017. The board supports Dr Slaoui’s decision and has agreed he will retire on June 30, 2017.
Dr. Slaoui will remain a member of the board until March 31, 2017. From April 1, 2017 until his retirement on June 30, 2017, he will serve as an advisor to both GSK and the board. Dr Slaoui joined GSK in 1988 and the board in 2006.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription